Small Insider Sale by DexCom Chief Legal Officer Reported on Form 4

Rhea-AI Filing Summary

On June 16, 2025, DexCom, Inc. (DXCM) Executive Vice President & Chief Legal Officer Michael Jon Brown sold 500 shares of common stock at $82.80 per share, according to a Form 4 filed on June 18, 2025. The trade was executed under a Rule 10b5-1 trading plan adopted on February 21, 2025, which pre-schedules transactions to reduce the appearance of information-based trading.

Following the sale, Brown’s beneficial ownership stands at 95,102 shares, including 86,490 unvested restricted stock units that vest through 2028. No derivative security activity was reported and there are no indications of changes in Brown’s role or corporate strategy. The 500-share sale represents roughly 0.5 % of his reported holdings and is immaterial relative to DexCom’s total public float.

Insights

Financial Analyst

TL;DR: Very small, pre-planned insider sale; no impact on DXCM valuation.

The transaction involves only 500 shares—about 0.5 % of the executive’s stake—and was executed under a 10b5-1 plan, signalling routine portfolio diversification rather than a negative signal. With 95 k shares still held, including sizeable unvested RSUs, the executive remains strongly aligned with shareholder interests. From a market perspective, volume and dollar value (~$41k) are negligible versus DexCom’s daily trading volumes, so I view the filing as neutral, not price-moving.

Corporate Governance Expert

TL;DR: Sale complies with Rule 10b5-1; no governance red flags.

The use of a pre-established Rule 10b5-1 plan, disclosed in the filing, meets best-practice standards for reducing insider-trading risk. The executive continues to own a large equity position, preserving incentive alignment. No derivative trading, pledge activity, or unusual patterns are evident. Accordingly, the event is not considered impactful from a governance or control standpoint.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Brown Michael Jon

(Last) (First) (Middle)

6340 SEQUENCE DRIVE

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
DEXCOM INC [ DXCM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
06/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/16/2025		S		500(1)	D	$82.8	95,102(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On February 21, 2025, Mr. Brown adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Brown. The shares set forth above were sold pursuant to the 10b5-1 Plan.

2. Included in this number are 86,490 unvested restricted stock units, 29,922 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 22,798 of which were granted on March 8, 2025 and shall vest through March 8, 2027, 14,474 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 7,256 of which were granted on March 8, 2023 and shall vest through March 8, 2026, and 12,040 of which were granted on March 8, 2022 and shall vest through March 8, 2026.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Jereme M. Sylvain, as Attorney-in-Fact for Michael Jon Brown	06/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many DexCom (DXCM) shares did EVP Michael Jon Brown sell?

He sold 500 shares of common stock.

What was the sale price reported in the Form 4 filing?

The shares were sold at $82.80 per share.

How many DexCom shares does the executive own after the transaction?

Brown now beneficially owns 95,102 shares, including unvested RSUs.

Was the sale executed under a Rule 10b5-1 trading plan?

Yes. The filing states the shares were sold pursuant to a 10b5-1 plan adopted on February 21, 2025.

Does the Form 4 disclose any derivative security transactions?

No derivative securities were acquired or disposed of in this filing.